Global point of care
NAVICA™ Mobile APP and BinaxNOW™ COVID-19 Ag CARD
Taking COVID-19 testing to a new level
Designed to restore confidence in daily life
The revolutionary NAVICA™ app helps people navigate daily life in a new normal. NAVICA displays results from the 15-minute BinaxNOW™ COVID-19 Ag Card, a rapid antigen test, to help individuals make informed decisions.
This first-of-its-kind app, available at no-charge, allows people who test negative to get an encrypted temporary digital NAVICA Pass, similar to an airline boarding pass. NAVICA-enabled organizations will be able to verify an individual’s negative COVID-19 test results by scanning the individual’s digital NAVICA Pass to facilitate entry into facilities, along with hand-washing, social distancing, enhanced cleaning, and mask-wearing.
The BinaxNOW™ COVID-19 Ag Card test has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).*
Only available in the US.
Benefits
Navica App
Your role in the NAVICA process
As a NAVICA-enabled test center, you will use the NAVICA Administrator App to communicate encrypted BinaxNOW COVID-19 Ag Card test results to participants, allowing them to obtain a digital NAVICA Pass with a negative test result.
To conduct testing at your site, a CLIA-waived license is required per the FDA Emergency Use Authorization for BinaxNOW.
The NAVICA-BinaxNOW testing process is simple:
- Scan the participant’s NAVICA ID on their mobile device and verify photo ID match.
- Scan the unique QR code on the BinaxNOW COVID-19 Ag Card test to create a secure link between the participant and the test card.
- Perform the BinaxNOW COVID-19 Ag Card test, following the package insert instructions.
- Rescan the QR code on the test card to confirm the link and chain of custody between the BinaxNOW COVID-19 Ag Card test and the participant.
- Visually interpret the test result on the card and submit the positive or negative result accordingly via the NAVICA app.
BinaxNOW COVID-19 Ag Card
A Breakthrough Antigen Test
- Simple test procedure using a direct nasal swab
- Direct nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset.**
- Onboard extraction allows the swab to be directly inserted into the test card
- Cost-effective, high performing test designed for decentralized testing
- Room temperature storage
- Visually read results in 15 minutes - no instrument required
- Emergency Use Authorization (EUA) supports testing in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation†
Sign up to get notified when testing is available in your area.
Download App
Download NAVICA, the first-of-its-kind app, from both the App Store® and Google Play™ store.
Abbott believes the NAVICA app and BinaxNOW COVID-19 Ag Card test will help us recover a bit more freedom, confidence and normalcy in our everyday lives.
Abbott is taking COVID-19 testing to a new level
Learn more about our contributions to the COVID-19 response and our efforts to attack the pandemic on critical fronts – speed, simplicity, affordability, access and reliability – through the introduction of our innovative BinaxNOW COVID-19 Ag test and NAVICA mobile app.
Abbott is taking COVID-19 testing to a new level
Learn more about our contributions to the COVID-19 response and our efforts to attack the pandemic on critical fronts – speed, simplicity, affordability, access and reliability – through the introduction of our innovative BinaxNOW COVID-19 Ag test and NAVICA mobile app.
Abbott is taking COVID-19 testing to a new level
Learn more about our contributions to the COVID-19 response and our efforts to attack the pandemic on critical fronts – speed, simplicity, affordability, access and reliability – through the introduction of our innovative BinaxNOW COVID-19 Ag test and NAVICA mobile app.
Helpful Documents
PRODUCT DOCUMENTS
SPECIFICATIONS
- Method: Lateral Flow
- Time to Result: 15 minutes
- Sample Type: Direct nasal swab
- **Sensitivity (PPA): 97.1%
- **Specificity (NPA): 98.5%
- Kit Size: 40 Tests
- Kit Contents:
- 40 Test Cards
- 40 Nasal Swabs
- Positive Control Swab
- Reagent Bottle
- Package Insert
- Procedure Card
- 40 Patient COVID-19 Fact Sheets
- Healthcare Provider COVID-19 Fact Sheet
Product Code
| BinaxNOW™ COVID-19 Ag Card | Code |
|---|---|
| BinaxNOW™ COVID-19 Ag Card (40CT) | 195-000 |
| BinaxNOW™ COVID-19 Ag Card Control Kit (10 Positive) | 195-080 |
| COVID-19 Swab Transport Tube Accessory Pack (24 CT) | 190-010 |
FAQ's
what is the navica pass?
NAVICA will display a digital NAVICA Pass via a QR code, similar to an airline boarding pass. This allows organizations to verify negative test results—enabling people to move about with greater confidence.
how can i get navica?
NAVICA, the first-of-its-kind app, can be downloaded from both the App Store® and Google Play™ at no charge. Go to your app store and search NAVICA and download the blue NAVICA app.
what kind of test is used?
The BinaxNOW COVID-19 Ag Card is a rapid lateral flow antigen test administered by a healthcare professional. It tests for active infection in direct nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset. It provides a positive or negative result in 15 minutes with no instrument required.
References
Google Play and the Google Play Logo are trademarks of Google LLC.
App Store and the Apple Logo are trademarks of Apple Inc.
*The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
**Refer to the product package insert for full instructions and clinical data.
† Before testing patients, federal regulations require testing sites to have a CLIA certificate issued by CMS. Sites performing only waived tests must obtain a Certificate of Waiver by applying for this certification for each location performing testing. Learn more about CLIA
